Neurogait
Using AI to screen Curable Dementia and other Neurological disease
Startup Seed Health Tech & Life Sciences Est. 2019
🌐 WebsiteLinkedIn
Total Raised
Undisclosed
Seed
Last Round
Undisclosed
1 rounds
Investors
1
1 public
Team
4
1-10 employees
Confidence
97/100
News
1
articles
About
Neurogait is developing AI based clinical screening for curable dementia, Parkinson's and other neurodegenerative Disease. It has conducted a successful clinical trial in Sheba Medical center and is an innovative Partner of Sheba ARC Innovation arm. It is currently pursuing clinical pilots in the EU and is in the process of applying for an MDR CE as a type 2a Medical device.
Classification
Sector
Health Tech & Life SciencesMedical DevicesDiagnostics DevicesDigital HealthcareDigital Medical Diagnostics
Core Technology
SensingArtificial IntelligenceDeep LearningComputer VisionMachine Learning
Target Customer
Healthcare & Life SciencesHealthcareProvidersPatientsMedical Devices Industry
Business Model
B2B2CB2B
Tags
deep-learningneurosciencedigital-healthcaremachine-learningneurologyartificial-intelligencealzheimers-diseasecomputer-visionparkinsonhome-caremedical-technologiesmachine-visiondiagnosticssensorsearly-detectionmedical-devices
Funding & Events
Jul 2019
Seed Undisclosed
Lisa Ansell (Lead)
News (1)
Growth-Positive
Neurogait: Creating an AI-based ecosystem for neurological disease
CustomersPartnersExpand
Details
Product Stage
Beta
Employees
1-10
Exact Count
3
District
Center District
Founded
2019
Registrar
516062767
Locations
Ranana, Israel
Links
Website
www.neurogait.com/
LinkedIn
Profile
Admin
Last Update
Aug 10, 2025
Verified by
Yotam Maman
Claimed
Yes
Missing
video or image, markets
Team (4)
Eyal Fruchtman
Co-founder & CEO
Founder
Ben Francke
Co-founder
Founder
David Shalev
CHIEF OPERATING OFFICER
Eyal Fruchtman
Internal
Created by
Jenny Sotnik-Talisman (genys30@yahoo.com)
Created
2020-10-05T00:00:00.000Z
Last editor
Yotam Maman (yotamm1988@gmail.com)
Finder · Neurogait · 2026